EP1141395A1 - Polymorphisme nucleotidique unique dans un pyruvate deshydrogenase kinase isoenzyme 2 (pdk2) chez l'homme - Google Patents

Polymorphisme nucleotidique unique dans un pyruvate deshydrogenase kinase isoenzyme 2 (pdk2) chez l'homme

Info

Publication number
EP1141395A1
EP1141395A1 EP99962355A EP99962355A EP1141395A1 EP 1141395 A1 EP1141395 A1 EP 1141395A1 EP 99962355 A EP99962355 A EP 99962355A EP 99962355 A EP99962355 A EP 99962355A EP 1141395 A1 EP1141395 A1 EP 1141395A1
Authority
EP
European Patent Office
Prior art keywords
pdk2
gene
polymoφhism
embl accession
single nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99962355A
Other languages
German (de)
English (en)
Inventor
Rakesh Anand
John Edward Norris Morten
John Craig Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1141395A1 publication Critical patent/EP1141395A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des polymorphismes affectant le gène humain pyruvate déshydrogénase kinase isoenzyme 2 (PDK2), et notamment sur la découverte d'un polymorphisme nucléotidique unique dans la région codante du gène humain PDK2 et de deux polymorphismes nucléotidiques uniques dans la région 3' transduite du gène humain PDK2. Cette invention porte également sur des procédés et des matériaux permettant d'analyser le gène allélomorphe PDK2, et sur l'utilisation du polymorphisme de PDK2 dans le diagnostic et le traitement de pathologies telles que les diabètes, l'obésité et la septicémie dans lesquelles l'inhibition de PDK2 pourrait donner un résultat thérapeutique favorable.
EP99962355A 1998-12-23 1999-12-17 Polymorphisme nucleotidique unique dans un pyruvate deshydrogenase kinase isoenzyme 2 (pdk2) chez l'homme Withdrawn EP1141395A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9828256 1998-12-23
GBGB9828256.9A GB9828256D0 (en) 1998-12-23 1998-12-23 Chemical compounds
PCT/GB1999/004305 WO2000039331A1 (fr) 1998-12-23 1999-12-17 Polymorphisme nucleotidique unique dans un pyruvate deshydrogenase kinase isoenzyme 2 (pdk2) chez l'homme

Publications (1)

Publication Number Publication Date
EP1141395A1 true EP1141395A1 (fr) 2001-10-10

Family

ID=10844741

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99962355A Withdrawn EP1141395A1 (fr) 1998-12-23 1999-12-17 Polymorphisme nucleotidique unique dans un pyruvate deshydrogenase kinase isoenzyme 2 (pdk2) chez l'homme

Country Status (5)

Country Link
EP (1) EP1141395A1 (fr)
JP (1) JP2002533135A (fr)
AU (1) AU1872700A (fr)
GB (2) GB9828256D0 (fr)
WO (1) WO2000039331A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1247860A1 (fr) * 2001-04-06 2002-10-09 Pfizer Limited Structure cristalline de la pyruvate dehydrogenase kinase 2 (PDHK-2) et son utilisation dans des méthodes d'identification et de design de nouveaux ligands
WO2003018835A2 (fr) * 2001-08-23 2003-03-06 Hvidovre Hospital Procede de detection rapide d'haplotypes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0039331A1 *

Also Published As

Publication number Publication date
GB2361061A (en) 2001-10-10
AU1872700A (en) 2000-07-31
GB9828256D0 (en) 1999-02-17
WO2000039331A1 (fr) 2000-07-06
GB0111826D0 (en) 2001-07-04
JP2002533135A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
EP1007738A1 (fr) Procedes d'analyse des polymorphismes de synthese du ltc4 et utilisation diagnostique
US6448003B1 (en) Genotyping the human phenol sulfotransferbase 2 gene STP2
EP1203827B1 (fr) Polymorphismes dans le gène humain de KDR
EP1130123A2 (fr) Méthode diagnostique
WO2000079003A1 (fr) Polymorphismes du gene de hmg-coa reductase humaine
EP1141395A1 (fr) Polymorphisme nucleotidique unique dans un pyruvate deshydrogenase kinase isoenzyme 2 (pdk2) chez l'homme
US20020143162A1 (en) Methods
US8236497B2 (en) Methods of diagnosing cardiovascular disease
WO2009125851A1 (fr) Procédé pour la détection de l’efficacité d’un composé de type dérivé de phénylalanine chez un patient diabétique
EP1100963A2 (fr) Polymorphismes du gene ccr-2 de l'homme
EP1100962A1 (fr) Polymorphismes genetiques du gene du recepteur neurokininique 1 de l'homme et leurs utilisations pour le diagnostic et le traitement d'affections
EP1112381A1 (fr) Polymorphismes du gene humain de la sous-unite alpha 4 de l'integrine, appropries au diagnostic et au traitement des maladies mediees par un ligand d'integrine
US20030190607A1 (en) Methods
US20030223986A1 (en) Methods
WO2005117859A2 (fr) Diagnostic d'affection cardiovasculaire
EP1114183A1 (fr) Polymorphismes du gene humain de la sous-unite beta 1 de l'integrine, appropries au diagnostic et au traitement des maladies mediees par un ligand d'integrine
EP1114182A1 (fr) Polymorphismes du gene humain vcam-1, appropries au diagnostic et traitement des maladies mediees par un ligand vcam-1
EP1100961A1 (fr) Polymorphismes genetiques dans le gene du recepteur humain des neurokinines 2 et leur utilisation dans le diagnostic et traitement de maladies
US20020160362A1 (en) Diagnostic method
US8080374B2 (en) Methods of diagnosing cardiovascular disease
US20030157484A1 (en) Chemical compounds
WO2000034515A1 (fr) Utilisation du polymorphisme du facteur x dans le diagnostic et le traitement d'affections induites par le facteur x et/ou xa
WO2006073183A1 (fr) Procede d'evaluation d'une maladie inflammatoire au moyen d'un polymorphisme de nucleotide simple
EP1184465A2 (fr) Procédé pour le diagnostic des polymorphismes de MCT-1 humain et des agents associés avec ces polymorphismes
JP2004141013A (ja) 糖尿病の発症危険性判定方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060530